Clinical Trial Update: Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD [Phase 4]

View source ↗

Summary

A Phase 4 trial update assesses immunogenicity, safety of a third BBIBP-CorV dose, and immune persistence in elderly individuals with chronic bronchitis and COP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BBIBP-CcorV (BBIBP-CorV)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19, Chronic Bronchitis | Phase 4 | Status: UNKNOWN